PYC Therapeutics Limited Share Price
Stocks
PYC
AU000000PYC7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.995 AUD | +9.62% |
|
+22.77% | +20.54% |
| 08:30am | ASX Biggest Gainers | MT |
| 29/07 | PYC Therapeutics Secures Approval for Higher Dosage in Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease | MT |
| Market Cap | 179Cr 125.26Cr 108.86Cr 101.64Cr 93Cr 175.93Cr 12TCr 1.2TCr 469.37Cr 5.95TCr 470.51Cr 460.09Cr 20TCr | P/E 2026 * |
-25.9x | P/E 2027 * | -19.7x |
|---|---|---|---|---|---|
| Enterprise Value | 112.57Cr 79Cr 68Cr 64Cr 59Cr 110.64Cr 7.51TCr 753.7Cr 295.19Cr 3.74TCr 295.9Cr 289.35Cr 12TCr | EV / Sales 2026 * |
307x | EV / Sales 2027 * | - |
| Free-Float |
70.64% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PYC Therapeutics Limited
| 17/03 | Bell Potter rates PYC as Speculative Buy | AQ |
| 09/25/09 | Bell Potter rates PYC as Speculative Buy | AQ |
| 07/24/07 | PYC Therapeutics : Anti Bribery & Anti Corruption Policy | PU |
| 07/24/07 | PYC Therapeutics : Definition of Independence | PU |
| 07/24/07 | PYC Therapeutics : Continuous Disclosure Policy | PU |
| 1 day | +9.62% | ||
| 1 week | +22.77% | ||
| Current month | +17.35% | ||
| 1 month | +28.30% | ||
| 3 months | +65.56% | ||
| 6 months | +32.12% | ||
| Current year | +20.54% |
| 1 week | 1.62 |  | 2.01 |
| 1 month | 1.49 | | 2.01 |
| Current year | 1.04 | | 2.01 |
| 1 year | 0.85 | | 2.01 |
| 3 years | 0.52 | | 2.1 |
| 5 years | 0.5 | | 2.1 |
| 10 years | 0.14 | | 2.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
CEO | Chief Executive Officer | 42 | 19/08/2020 |
Thomas Ulmer
DFI | Director of Finance/CFO | 47 | 07/07/2026 |
Sri Mudumba
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
BRD | Director/Board Member | 42 | 30/11/2018 |
Ian Constable
BRD | Director/Board Member | - | 22/09/2025 |
Peter Coleman
CHM | Chairman | 66 | 18/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 23/12/25 | Free | Chairman | 20,00,000 | 0.3429% | ||
| 26/11/25 | Buy | Chief Executive Officer | 1,33,350 | 0.0229% | ||
| 27/02/25 | Australia Land Pty Ltd.
| Buy | Company | 2,80,00,000 | 6.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.62% | +22.77% | +64.88% | +243.97% | 125.26Cr | |
| +0.32% | +0.79% | -0.18% | +14.52% | 4.82TCr | |
| -2.71% | -2.99% | +398.09% | +472.12% | 3.88TCr | |
| -0.71% | +9.45% | +27.90% | +7.89% | 3.84TCr | |
| -0.71% | -3.72% | +4.94% | +52.45% | 3.49TCr | |
| -2.41% | +1.96% | +11.68% | +38.17% | 2.92TCr | |
| -0.66% | -2.73% | +35.50% | +122.17% | 1.6TCr | |
| -0.19% | -3.93% | - | - | 1.6TCr | |
| +0.74% | -0.41% | +2.55% | +15.82% | 1.35TCr | |
| -3.15% | -6.14% | -4.82% | -36.90% | 1.22TCr | |
| Average | +0.02% | +0.14% | +60.06% | +103.36% | 2.49TCr | |
| Weighted average by Cap. | -0.97% | +0.19% | +75.88% | +104.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 36.67L 25.66L 22.3L 20.82L 19.11L 36.04L 24Cr 2.45Cr 96.15L 12Cr 96.38L 94.25L 40Cr | - |
| Net income | -5.74Cr -4.02Cr -3.49Cr -3.26Cr -2.99Cr -5.64Cr -383.08Cr -38Cr -15Cr -191.04Cr -15Cr -15Cr -630.1Cr | -8.58Cr -6Cr -5.22Cr -4.87Cr -4.47Cr -8.43Cr -571.96Cr -57Cr -22Cr -285.23Cr -23Cr -22Cr -940.78Cr |
| Net Debt | -66Cr -46Cr -40Cr -38Cr -35Cr -65Cr -4.43TCr -444.74Cr -174.18Cr -2.21TCr -174.61Cr -170.74Cr -7.29TCr | -58Cr -41Cr -35Cr -33Cr -30Cr -57Cr -3.86TCr -387.49Cr -151.76Cr -1.93TCr -152.13Cr -148.76Cr -6.35TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | A$1.995 | +9.62% | 34,35,046 |
| 03/26/03 | A$1.820 | +7.06% | 23,71,962 |
| 31/26/31 | A$1.700 | +1.49% | 6,65,496 |
| 30/26/30 | A$1.675 | +3.08% | 27,78,064 |
| 29/26/29 | A$1.625 | 0.00% | 16,99,137 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PYC Stock
Select your edition
All financial news and data tailored to specific country editions
